influenza vaccines


Summary: Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.

Top Publications

  1. pmc Emergence and pandemic potential of swine-origin H1N1 influenza virus
    Gabriele Neumann
    Department of Pathobiological Sciences, University of Wisconsin Madison, Madison, Wisconsin 53711, USA
    Nature 459:931-9. 2009
  2. ncbi Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
    Michael T Osterholm
    Center for Infectious Disease Research and Policy, University of Minnesota, MN 55455, USA
    Lancet Infect Dis 12:36-44. 2012
  3. pmc Antibody recognition of a highly conserved influenza virus epitope
    Damian C Ekiert
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 324:246-51. 2009
  4. pmc The transmissibility and control of pandemic influenza A (H1N1) virus
    Yang Yang
    Center for Statistics and Quantitative Infectious Diseases, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA
    Science 326:729-33. 2009
  5. pmc Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus
    Rui Xu
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 328:357-60. 2010
  6. ncbi Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010
    Anthony E Fiore
    Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, N E, MS A 20, Atlanta, GA 30333, USA
    MMWR Recomm Rep 59:1-62. 2010
  7. pmc Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada
    Danuta M Skowronski
    British Columbia Centre for Disease Control BCCDC, Vancouver, British Columbia, Canada
    PLoS Med 7:e1000258. 2010
  8. pmc Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
    Patrick J Lillie
    Jenner Institute, University of Oxford, UK
    Clin Infect Dis 55:19-25. 2012
  9. pmc Systems biology of vaccination for seasonal influenza in humans
    Helder I Nakaya
    Emory Vaccine Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:786-95. 2011
  10. pmc Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains
    John J Treanor
    Department of Medicine, University of Rochester Medical Center, NY, USA
    Clin Infect Dis 55:951-9. 2012

Detail Information

Publications389 found, 100 shown here

  1. pmc Emergence and pandemic potential of swine-origin H1N1 influenza virus
    Gabriele Neumann
    Department of Pathobiological Sciences, University of Wisconsin Madison, Madison, Wisconsin 53711, USA
    Nature 459:931-9. 2009
  2. ncbi Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
    Michael T Osterholm
    Center for Infectious Disease Research and Policy, University of Minnesota, MN 55455, USA
    Lancet Infect Dis 12:36-44. 2012
    No published meta-analyses have assessed efficacy and effectiveness of licensed influenza vaccines in the USA with sensitive and highly specific diagnostic tests to confirm influenza.
  3. pmc Antibody recognition of a highly conserved influenza virus epitope
    Damian C Ekiert
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 324:246-51. 2009
    ..The CR6261 epitope identified here should accelerate the design and implementation of improved vaccines that can elicit CR6261-like antibodies, as well as antibody-based therapies for the treatment of influenza...
  4. pmc The transmissibility and control of pandemic influenza A (H1N1) virus
    Yang Yang
    Center for Statistics and Quantitative Infectious Diseases, Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA
    Science 326:729-33. 2009
    ..If a vaccine were available soon enough, vaccination of children, followed by adults, reaching 70% overall coverage, in addition to high-risk and essential workforce groups, could mitigate a severe epidemic...
  5. pmc Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus
    Rui Xu
    Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 328:357-60. 2010
    ..Thus, antigenic similarity between the 2009 and 1918-like viruses provides an explanation for the age-related immunity to the current influenza pandemic...
  6. ncbi Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010
    Anthony E Fiore
    Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, N E, MS A 20, Atlanta, GA 30333, USA
    MMWR Recomm Rep 59:1-62. 2010
    ..vaccine for persons aged >or=65 years; and 5) information about other standard-dose newly approved influenza vaccines and previously approved vaccines with expanded age indications...
  7. pmc Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada
    Danuta M Skowronski
    British Columbia Centre for Disease Control BCCDC, Vancouver, British Columbia, Canada
    PLoS Med 7:e1000258. 2010
    ..Several epidemiologic investigations were conducted through the summer to assess this putative association...
  8. pmc Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
    Patrick J Lillie
    Jenner Institute, University of Oxford, UK
    Clin Infect Dis 55:19-25. 2012
    ..Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers...
  9. pmc Systems biology of vaccination for seasonal influenza in humans
    Helder I Nakaya
    Emory Vaccine Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:786-95. 2011
    ..Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines...
  10. pmc Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains
    John J Treanor
    Department of Medicine, University of Rochester Medical Center, NY, USA
    Clin Infect Dis 55:951-9. 2012
    b>Influenza vaccines may be reformulated annually because of antigenic drift in influenza viruses. However, the relationship between antigenic characteristics of circulating viruses and vaccine effectiveness (VE) is not well understood...
  11. ncbi A novel influenza A (H1N1) vaccine in various age groups
    Feng Cai Zhu
    Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
    N Engl J Med 361:2414-23. 2009
    ..There is an urgent need for a vaccine that is effective against the 2009 pandemic influenza A (H1N1) virus...
  12. ncbi Strategies for mitigating an influenza pandemic
    Neil M Ferguson
    Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, St Mary s Campus, Norfolk Place, London W2 1PG, UK
    Nature 442:448-52. 2006
    ..Estimates of policy effectiveness will change if the characteristics of a future pandemic strain differ substantially from those seen in past pandemics...
  13. ncbi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
    ..We therefore report preliminary safety and immunogenicity results after one injection of a licensed monovalent pandemic H1N1 vaccine in the USA...
  14. pmc Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines
    Marine L B Hillaire
    Department of Virology, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    J Biomed Biotechnol 2011:939860. 2011
    There is considerable interest in the development of broadly protective influenza vaccines because of the continuous emergence of antigenic drift variants of seasonal influenza viruses and the threat posed by the emergence of ..
  15. ncbi The 2009 A (H1N1) influenza virus pandemic: A review
    Marc P Girard
    University Paris 7 Denis Diderot, 39 rue Seignemartin, 69008, Lyon, France
    Vaccine 28:4895-902. 2010
    ..including new manufacturers from China, Thailand, India and South America, to develop pandemic H1N1 influenza vaccines. All currently registered vaccines were tested for safety and immunogenicity in clinical trials on human ..
  16. ncbi Antibody response to influenza vaccination in the elderly: a quantitative review
    Katherine Goodwin
    National Institutes of Allergy and Infectious Diseases, Office of Global Affairs, 6610 Rockledge Drive, Room 2033, Bethesda, MD 20818, USA
    Vaccine 24:1159-69. 2006
    ..We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly...
  17. pmc Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
    Tamara K Berthoud
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    Clin Infect Dis 52:1-7. 2011
    Influenza A viruses cause occasional pandemics and frequent epidemics. Licensed influenza vaccines that induce high antibody titers to the highly polymorphic viral surface antigen hemagglutinin must be re-formulated and readministered ..
  18. ncbi Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines
    R J Cox
    Influenza Research Centre Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway
    Scand J Immunol 59:1-15. 2004
    ..provides an update of the current status on influenza vaccination and concentrates on the two main types of influenza vaccines currently in use, namely the cold-adapted vaccine (CAV) given intranasally/orally, and the inactivated ..
  19. pmc I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe
    Esther Kissling
    EpiConcept, Paris, France
    PLoS ONE 6:e27622. 2011
  20. ncbi Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine
    C R Simpson
    Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, UK
    Health Technol Assess 14:313-46. 2010
  21. ncbi Optimizing influenza vaccine distribution
    Jan Medlock
    Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520 8034, USA
    Science 325:1705-8. 2009
    ..indicate that consideration of age-specific transmission dynamics is paramount to the optimal allocation of influenza vaccines. We also found that previous and new recommendations from the U.S...
  22. ncbi Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study
    Joan Puig-Barbera
    Health Promotion Unit, Centro de Salud Pública, Avda del Mar, 12, 12003 Castellón, Spain
    Vaccine 28:7460-7. 2010
    ..No effect was observed for the 2008-2009 and 2009-2010 seasonal influenza vaccines. However, the pandemic vaccine was associated with an adjusted vaccine effectiveness of 90% (95% CI, 48-100%)..
  23. ncbi Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine
    Tristan W Clark
    Infectious Diseases Unit, University Hospitals Leicester, and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, United Kingdom
    N Engl J Med 361:2424-35. 2009
    ..The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority...
  24. ncbi Response to a monovalent 2009 influenza A (H1N1) vaccine
    Michael E Greenberg
    Clinical Research and Development, CSL, Parkville, Vic, Australia
    N Engl J Med 361:2405-13. 2009
    ..A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia...
  25. ncbi Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis
    Santiago Echevarría-Zuno
    Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social, Mexico City, Mexico
    Lancet 374:2072-9. 2009
    ..We report the timing and spread of H1N1 in cases, and explore protective and risk factors for infection, severe disease, and death...
  26. pmc Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine
    Davide Corti
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    J Clin Invest 120:1663-73. 2010
    ..These findings reveal that seasonal influenza vaccination can induce polyclonal heterosubtypic neutralizing antibodies that cross-react with the swine-origin pandemic H1N1 influenza virus and with the highly pathogenic H5N1 virus...
  27. ncbi Effectiveness of maternal influenza immunization in mothers and infants
    K Zaman
    International Centre for Diarrheal Disease Research, Dhaka, Bangladesh
    N Engl J Med 359:1555-64. 2008
    ..We assessed the clinical effectiveness of inactivated influenza vaccine administered during pregnancy in Bangladesh...
  28. pmc AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland
    Hanna Nohynek
    Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
    PLoS ONE 7:e33536. 2012
    ..A sudden increase in childhood narcolepsy was observed in Finland soon after pandemic influenza epidemic and vaccination with ASO3-adjuvanted Pandemrix. No increase was observed in other age groups...
  29. ncbi Induction of broadly neutralizing H1N1 influenza antibodies by vaccination
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892 3005, USA
    Science 329:1060-4. 2010
    The rapid dissemination of the 2009 pandemic influenza virus underscores the need for universal influenza vaccines that elicit protective immunity to diverse viral strains...
  30. pmc Programming the magnitude and persistence of antibody responses with innate immunity
    Sudhir Pai Kasturi
    Emory Vaccine Center, Emory University, Atlanta, Georgia 30329, USA
    Nature 470:543-7. 2011
    ..Immunization protected completely against lethal avian and swine influenza virus strains in mice, and induced robust immunity against pandemic H1N1 influenza in rhesus macaques...
  31. ncbi Time lines of infection and disease in human influenza: a review of volunteer challenge studies
    Fabrice Carrat
    Universite Pierre et Marie Curie PARIS6, UMR S 707, Paris, France
    Am J Epidemiol 167:775-85. 2008
  32. ncbi Influenza
    Karl G Nicholson
    Infectious Diseases Unit, Leicester Royal Infirmary, Leicester, UK
    Lancet 362:1733-45. 2003
  33. ncbi Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine
    Carrie Reed
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30033, United States
    Vaccine 30:1993-8. 2012
    ..The additional protection provided by including a second lineage of influenza B could result in a modest reduction in influenza-associated outcomes...
  34. ncbi Influenza
    N J Cox
    Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Lancet 354:1277-82. 1999
    ..three decades, efforts to prevent and control influenza have focused primarily on the use of inactivated influenza vaccines in elderly people and in individuals with chronic medical conditions that put them at risk for complications...
  35. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    Changes in influenza viruses require regular reformulation of strain-specific influenza vaccines. Vaccines based on conserved antigens provide broader protection...
  36. pmc Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
    Claire S Waddington
    Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7LJ
    BMJ 340:c2649. 2010
    ..To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom...
  37. ncbi Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong
    Benjamin J Cowling
    Infectious Disease Epidemiology Group, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
    Clin Infect Dis 51:1370-9. 2010
    ..The relationship between seasonal influenza vaccine and susceptibility to 2009 pandemic A/H1N1 virus infection is not fully understood...
  38. pmc Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus
    Mark W Lamere
    Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Immunol 186:4331-9. 2011
    ..The high conservation of NP Ag and the known longevity of Ab responses suggest that anti-NP IgG may provide a critically needed component of a universal influenza vaccine...
  39. pmc Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses
    Graeme E Price
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, United States of America
    PLoS ONE 5:e13162. 2010
    The sudden emergence of novel influenza viruses is a global public health concern. Conventional influenza vaccines targeting the highly variable surface glycoproteins hemagglutinin and neuraminidase must antigenically match the emerging ..
  40. ncbi Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus
    Kathy Hancock
    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    N Engl J Med 361:1945-52. 2009
  41. ncbi Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
    Xiao Feng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Lancet 375:56-66. 2010
    ..The current influenza pandemic calls for a safe and effective vaccine. We assessed the safety and immunogenicity of eight formulations of 2009 pandemic influenza A H1N1 vaccine produced by ten Chinese manufacturers...
  42. ncbi Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
    Anthony E Fiore
    Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA 30333, USA
    MMWR Recomm Rep 58:1-52. 2009
    ..These recommendations also include a summary of safety data for U.S. licensed influenza vaccines. These recommendations and other information are available at CDC's influenza website (http://www.cdc...
  43. ncbi H5N1 influenza--continuing evolution and spread
    Robert G Webster
    Department of Infectious Diseases, Division of Virology, St Jude Children s Research Hospital, Memphis, TN, USA
    N Engl J Med 355:2174-7. 2006
  44. pmc Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009
    Yanbing Li
    Animal Influenza Laboratory of the Ministry of Agriculture and National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, CAAS, 427 Maduan Street, Harbin 150001, People s Republic of China
    J Virol 84:8389-97. 2010
    ..Our results demonstrate that the H5N1 AIVs circulating in nature have complex biological characteristics and pose a continued challenge for disease control and pandemic preparedness...
  45. pmc Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
    Jens Wrammert
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nature 453:667-71. 2008
    ..However, we found that most of the influenza-virus-specific mAbs showed the highest affinity for the current vaccine strain. Thus, OAS does not seem to be a common occurrence in normal, healthy adults receiving influenza vaccination...
  46. ncbi Effectiveness of influenza vaccine in the community-dwelling elderly
    Kristin L Nichol
    Medicine Service and Center for Chronic Disease Outcomes Research, Minneapolis Veterans Affairs Medical Center and University of Minnesota, Minneapolis 55417, USA
    N Engl J Med 357:1373-81. 2007
    ..This study examined the effectiveness of influenza vaccine in seniors over the long term while addressing potential bias and residual confounding in the results...
  47. ncbi Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial
    Terry Nolan
    Vaccine and Immunization Research Group, School of Population Health, University of Melbourne, and Murdoch Children s Research Institute, Victoria, Australia
    JAMA 303:37-46. 2010
    ..In the ongoing influenza pandemic, a safe and effective vaccine against 2009 influenza A(H1N1) is needed for infants and children...
  48. pmc Glycans on influenza hemagglutinin affect receptor binding and immune response
    Cheng Chi Wang
    Genomics Research Center, Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica, Taipei 115, Taiwan
    Proc Natl Acad Sci U S A 106:18137-42. 2009
    ..Thus, removal of structurally nonessential glycans on viral surface glycoproteins may be a very effective and general approach for vaccine design against influenza and other human viruses...
  49. pmc Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments
    Michael Schotsaert
    Department for Molecular Biomedical Research, Ghent University Technologpierpark 927, B 9052 Ghent, Belgium
    Expert Rev Vaccines 8:499-508. 2009
    b>Influenza vaccines used today are strain specific and need to be adapted every year to try and match the antigenicity of the virus strains that are predicted to cause the next epidemic...
  50. ncbi Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation
    Marc Baguelin
    Centre for Infections, Health Protection Agency, United Kingdom
    Vaccine 28:2370-84. 2010
    ..In countries where the epidemic is not so far advanced vaccination of children may be cost-effective. Similar, detailed, real-time modelling and economic studies could help to clarify the situation...
  51. ncbi Protective effect of single-dose adjuvanted pandemic influenza vaccine in children
    P G Van Buynder
    New Brunswick Department of Health, Office of the Chief Medical Officer of Health OCMOH, Fredericton, NB, Canada
    Influenza Other Respir Viruses 4:171-8. 2010
    ..25 ml of the GSK adjuvanted vaccine (Arepanrix) equivalent to 1.9 microg HA. Children 6 months to 35 months received two doses as did those 36-119 months with chronic medical conditions...
  52. ncbi Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
    Alfonso Carmona
    Insituto Hispalense de Pediatría, Sevilla, Spain
    Vaccine 28:5837-44. 2010
    ..9microg HA in children 6-35 months old is highly immunogenic and that the overall reactogenicity profile is acceptable although reactions including fever tend to increase after a second dose...
  53. pmc Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel
    Matthew C Johns
    Division of GEIS Operations, Armed Forces Health Surveillance Center, Silver Spring, Maryland, United States of America
    PLoS ONE 5:e10722. 2010
    ..A novel A/H1N1 virus is the cause of the present influenza pandemic; vaccination is a key countermeasure, however, few data assessing prior seasonal vaccine effectiveness (VE) against the pandemic strain of H1N1 (pH1N1) virus are available...
  54. pmc Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses
    Ken M Kunisaki
    Pulmonary Section, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Lancet Infect Dis 9:493-504. 2009
    ..Randomised clinical trial data were limited to one study of HIV-infected patients with high vaccine efficacy. Better trial data would inform vaccination recommendations on the basis of efficacy and cost in these at-risk populations...
  55. ncbi Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity
    Andrea Jegerlehner
    Cytos Biotechnology, Schlieren, Switzerland
    J Immunol 172:5598-605. 2004
  56. ncbi Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
    Suzanne L Epstein
    Laboratory of Immunology and Developmental Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Bethesda, MD 20852, USA
    Vaccine 23:5404-10. 2005
    ..Thus, gene-based vaccination with NP may contribute to protective immunity against diverse influenza viruses through its ability to stimulate cellular immunity...
  57. ncbi Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
    T Jefferson
    Cochrane Vaccines Field, ASL 20, 15100 Alessandria, Italy
    Lancet 366:1165-74. 2005
    Influenza vaccination of elderly individuals is recommended worldwide. Our aim was to review the evidence of efficacy and effectiveness of influenza vaccines in individuals aged 65 years or older.
  58. ncbi T cell responses are better correlates of vaccine protection in the elderly
    Janet E McElhaney
    Center for Immunotherapy of Cancer and Infectious Diseases, MC1601, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1601, USA
    J Immunol 176:6333-9. 2006
    ..Ex vivo measures of the cell-mediated immune response should be incorporated into evaluation of new vaccines for older adults...
  59. pmc Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
    Marta Valenciano
    EpiConcept, Paris, France
    PLoS Med 8:e1000388. 2011 European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (..
  60. pmc Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development
    Zuzana Staneková
    Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic
    Virol J 7:351. 2010
  61. pmc Modelling mitigation strategies for pandemic (H1N1) 2009
    Marija Zivkovic Gojovic
    Toronto Health Economics and Technology Assessment Collaborative, University of Toronto, Research Institute of the Hospital for Sick Children, Toronto, ON
    CMAJ 181:673-80. 2009
    ..Simulation models can be used to project the effectiveness of mitigation strategies, but the choice of the best scenario may change depending on model assumptions and uncertainties...
  62. ncbi Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial
    Mark Loeb
    Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St W, Hamilton, ON, L8N 3Z5 Canada
    JAMA 303:943-50. 2010
    ..Children and adolescents appear to play an important role in the transmission of influenza. Selectively vaccinating youngsters against influenza may interrupt virus transmission and protect those not immunized...
  63. pmc Optimizing infectious disease interventions during an emerging epidemic
    Jacco Wallinga
    Centre for Infectious Disease Control, National Institute for Public Health and the Environment, 3720 BA Bilthoven, Netherlands
    Proc Natl Acad Sci U S A 107:923-8. 2010
  64. ncbi Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial
    Zoltan Vajo
    University of Debrecen, Medical and Health Sciences Centre, Debrecen, Hungary
    Lancet 375:49-55. 2010
    With the ongoing 2009 pandemic of influenza A H1N1, development of pandemic influenza vaccines has generated much interest...
  65. ncbi The annual production cycle for influenza vaccine
    Catherine Gerdil
    Aventis Pasteur S A, Campus Mérieux 1541, Av Marcel Mérieux, F 69280, Marcy l Etoile, France
    Vaccine 21:1776-9. 2003
    ..Major steps of this vaccine production process including the milestones and the bottlenecks need to be detailed in order to well understand difficulties and hurdles towards increase of global capacity and introduction of new vaccines...
  66. ncbi The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus
    Gunilla B Karlsson Hedestam
    Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Nat Rev Microbiol 6:143-55. 2008
    ..Efforts to develop broadly neutralizing vaccines against either HIV-1 or influenza virus might establish a paradigm for future vaccines against highly variable pathogens...
  67. ncbi The mechanism of action of MF59 - an innately attractive adjuvant formulation
    D T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA 02139, United States
    Vaccine 30:4341-8. 2012
    ..This recruitment appears to be triggered by the induction of a chemokine driven gradient by the impact of MF59 on local cells, which are activated to secrete further chemokines, which are recruitment factors for more immune cells...
  68. pmc Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study
    Joanne M Langley
    Canadian Center for Vaccinology, Departments of Pediatrics and Community Health and Epidemiology, IWK Health Centre and Dalhousie University, Halifax, Canada
    J Infect Dis 203:1729-38. 2011
    ..Highly pathogenic avian influenza H5N1 viruses remain a threat to human health, with potential to become pandemic agents...
  69. pmc Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study
    Qiuyan Liao
    Health Behaviours Research Group, Department of Community Medicine and School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China
    PLoS ONE 6:e17713. 2011
    ..However, a vaccination program's efficacy largely depends on population compliance. We examined general population decision-making for pH1N1 vaccination using a modified Theory of Planned Behaviour (TBP)...
  70. pmc Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine
    Benjamin J Cowling
    School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    Clin Infect Dis 54:1778-83. 2012
    ..40; 95% confidence interval: 1.31-14.8). Being protected against influenza, TIV recipients may lack temporary non-specific immunity that protected against other respiratory viruses...
  71. ncbi Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin
    James W Huleatt
    VaxInnate Corporation, 300 George Street, New Haven, CT 06511, USA
    Vaccine 26:201-14. 2008
    ..These data demonstrate that the linkage of specific TLR ligand with influenza M2e yields a vaccine candidate that offers significant promise for widespread protection against multiple influenza A virus strains...
  72. ncbi Factors associated with uptake of vaccination against pandemic influenza: a systematic review
    Alison Bish
    Department of Clinical, Educational and Health Psychology, University College London, 1 19 Torrington Place, London WC1E 7HB, UK
    Vaccine 29:6472-84. 2011
    ..A vaccination programme against H1N1 influenza was introduced in many countries from September 2009, but there was low uptake in both the general population and health professionals in many, though not all, countries...
  73. ncbi Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children
    Steven Black
    Center for Global Health, University of Cincinnati Children s Hospital, Cincinnati, OH 45229, USA
    Pediatr Infect Dis J 30:1081-5. 2011
    ..Neither seasonal nor challenge-based correlates have been evaluated in children...
  74. ncbi Maternal influenza vaccination and effect on influenza virus infection in young infants
    Angelia A Eick
    Center for American Indian Health, 621 N Washington Street, Baltimore, MD 21205, USA
    Arch Pediatr Adolesc Med 165:104-11. 2011
    ..To assess the effect of seasonal influenza vaccination during pregnancy on laboratory-confirmed influenza in infants to 6 months of age...
  75. ncbi Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
    Elly van Riet
    Influenza Virus Research Centre, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
    Vaccine 30:5893-900. 2012
    ..and IgA responses in mice were shown to also be involved in cross-protection, the research on mucosal influenza vaccines is currently expanding...
  76. pmc Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe
    Jeanne Dieleman
    Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
    BMJ 343:d3908. 2011
    ..To assess the association between pandemic influenza A (H1N1) 2009 vaccine and Guillain-Barré syndrome...
  77. pmc Impact of maternal immunization on influenza hospitalizations in infants
    Katherine A Poehling
    Department of Pediatrics, Wake Forest University School of Medicine, Winston Salem, NC, USA
    Am J Obstet Gynecol 204:S141-8. 2011
    ..30-0.91). Infants of vaccinated mothers were 45-48% less likely to have influenza hospitalizations than infants of unvaccinated mothers. Our results support the current influenza vaccination recommendation for pregnant women...
  78. ncbi Original antigenic sin responses to influenza viruses
    Jin Hyang Kim
    Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, Georgia 30329, USA
    J Immunol 183:3294-301. 2009
  79. pmc Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children
    Daniel F Hoft
    Department of Internal Medicine, Saint Louis University Vaccine and Treatment Evaluation Unit, Missouri, USA
    J Infect Dis 204:845-53. 2011
    Two doses of either trivalent live attenuated or inactivated influenza vaccines (LAIV and TIV, respectively) are approved for young children (≥ 24 months old for LAIV and ≥ 6 months old for TIV) and induce protective antibody ..
  80. pmc Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines
    Shih Chang Lin
    Institute of Biotechnology and Department of Life Science, National Tsing Hua University, Hsinchu, Taiwan
    PLoS ONE 6:e20052. 2011
    ..The highly pathogenic avian influenza (HPAI) H5N1 virus continues to cause disease in poultry and humans. The hemagglutinin (HA) envelope protein is the primary target for subunit vaccine development...
  81. pmc Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures
    Joshua G Petrie
    Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
    J Infect Dis 203:1309-15. 2011
    End points used to detect influenza in vaccine efficacy trials have varied. Both the inactivated and live attenuated influenza vaccines are efficacious; however, failure to protect occurs.
  82. pmc Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies
    Sanae Sasaki
    Department of Immunology and Microbiology, Stanford University School of Medicine, Stanford, California, USA
    J Clin Invest 121:3109-19. 2011
    ..They also suggest that exposure history affects the cross-reactivity of vaccination-induced antibodies...
  83. pmc Cell-mediated protection in influenza infection
    Paul G Thomas
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Emerg Infect Dis 12:48-54. 2006
    ..We discuss the advantages of developing a vaccine based on cell-mediated immune responses toward highly pathogenic influenza virus and potential problems arising from immune pressure...
  84. ncbi Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign
    Angie Bone
    Institut de veille sanitaire French Institute for Public Health Surveillance, 12 Rue du Val d Osne, 94415 Saint Maurice Cedex, France
    Vaccine 28:8157-61. 2010
    ..Vaccine uptake in pregnant women was 22.7%. These low uptakes may reflect controversies around the vaccine and vaccination policy and have important implications for future pandemic vaccination strategies...
  85. ncbi Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial
    Karl G Nicholson
    Infectious Diseases Unit, Vaccine Evaluation Centre, University Hospitals of Leicester NHS Trust and Department of Infection, Immunity, and Inflammation, University of Leicester, UK
    Lancet Infect Dis 11:91-101. 2011
    ..We assessed the safety and immunogenicity in adults in the UK of pandemic H1N1 whole-virion vaccine and oil-in-water adjuvanted vaccine purchased by the UK government in 2009...
  86. ncbi Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains
    Vernon J Lee
    Biodefence Center, Singapore Armed Forces, 701 Transit Road 04 01, Singapore 778910, Singapore
    Vaccine 28:6852-7. 2010
    ..In June 2009, we conducted a prospective study in Singapore on 51 individuals to determine their serologic responses before and following receipt of the 2009 Southern Hemisphere seasonal influenza vaccine...
  87. pmc HIV-1 and influenza antibodies: seeing antigens in new ways
    Peter D Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 10:573-8. 2009
    ..We outline how each of these different modes of antibody recognition is particularly suited to overcoming a specific viral evasion tactic and assess potential routes of re-elicitation in vaccine settings...
  88. ncbi Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals
    Pablo Tebas
    University of Pennsylvania School of Medicine, Philadelphia, USA
    AIDS 24:2187-92. 2010
    ..To evaluate the safety and immunogenicity of the H1N1 2009 vaccine in HIV-positive individuals...
  89. ncbi Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model
    Karen L Laurie
    World Health Organization Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    J Infect Dis 202:1011-20. 2010
    ..The contribution of preexisting immunity to seasonal influenza to protection against A(H1N1)pdm infection was analyzed in a ferret model...
  90. pmc Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins
    Taia T Wang
    Department of Microbiology Mount Sinai School of Medicine New York, New York, United States of America
    PLoS Pathog 6:e1000796. 2010
    ..This mutability of structural determinants of protective immunity is the obstacle in developing universal influenza vaccines. Towards the development of such vaccines and other immune therapies, our studies are designed to identify ..
  91. pmc Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum
    Alison P Galvani
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA
    Proc Natl Acad Sci U S A 104:5692-7. 2007
    ..Our results reveal possible strategies to bring Nash and utilitarian vaccination levels into alignment...
  92. ncbi Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis
    A Anema
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    HIV Med 9:57-61. 2008
    ..Evidence supporting this recommendation is limited. We assessed the efficacy of influenza vaccines in preventing influenza in HIV-positive patients through a systematic review and meta-analysis.
  93. ncbi Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform
    Jérôme Denis
    Centre de Recherche en Infectiologie, Pavillon CHUL, Universite Laval, 2705 Boulevard Laurier, Quebec, PQ, G1V 4G2 Canada
    Vaccine 26:3395-403. 2008
    ..virulent influenza viruses and the consequent risk of pandemics, new approaches to designing universal influenza vaccines are urgently needed...
  94. ncbi Haemagglutination-inhibiting antibody to influenza virus
    J C de Jong
    National Influenza Centre, Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
    Dev Biol (Basel) 115:63-73. 2003
    ..However, even in completely healthy elderly individuals the response to vaccination with an antigenically new virus may be strongly reduced compared with younger vaccinees...
  95. pmc Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates
    Jason T Weinfurter
    Wisconsin National Primate Research Center, Madison, Wisconsin, United States of America
    PLoS Pathog 7:e1002381. 2011
    ..Vaccines capable of inducing such cross-reactive T cells may help protect humans against severe disease caused by newly emerging pandemic influenza viruses...
  96. pmc Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants
    Isaac Benowitz
    Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06520 8064, USA
    Clin Infect Dis 51:1355-61. 2010
    ..Vaccination of women during pregnancy may protect the infant through transfer of antibodies from the mother. Few studies have examined the effectiveness of this strategy, and those studies produced mixed results...
  97. ncbi Mortality benefits of influenza vaccination in elderly people: an ongoing controversy
    Lone Simonsen
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Lancet Infect Dis 7:658-66. 2007
    ..The remaining evidence base is currently insufficient to indicate the magnitude of the mortality benefit, if any, that elderly people derive from the vaccination programme...
  98. pmc Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes
    Taia T Wang
    Department of Microbiology and Medicine, Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 107:18979-84. 2010
    ..These results provide proof of concept for an HA2-based influenza vaccine that could diminish the threat of pandemic influenza disease and generally reduce the significance of influenza viruses as human pathogens...
  99. ncbi The need for quadrivalent vaccine against seasonal influenza
    Robert B Belshe
    Saint Louis University School of Medicine, USA
    Vaccine 28:D45-53. 2010 the United States of America (USA), the Food and Drug Administration (FDA), recommend trivalent seasonal influenza vaccines containing the two main influenza type A strains and, due to its lesser but still important prevalence, one ..
  100. pmc Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
    Grazia Galli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Proc Natl Acad Sci U S A 106:3877-82. 2009
    ..We suggest that CD4(+) T cell priming might be used as an early predictor of the immunogenicity of prepandemic vaccines...
  101. ncbi Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness
    Evan W Orenstein
    Yale University, New Haven, CT, USA
    Int J Epidemiol 36:623-31. 2007

Research Grants73

  1. Cellular Immunity to Category A-C Viruses in Humans
    ROBERT WILLIAM FINBERG; Fiscal Year: 2013
    ..of this project is to define the human T-cell responses to influenza infection and to trivalent inactivated influenza vaccines (TIV) in younger and older adults...
    Rafi Ahmed; Fiscal Year: 2013
    ..human memory T and B cell responses not only to YFV but also after immunization with small pox and influenza vaccines. In this renewal application we will focus our studies on CD8 T cells and examine the mechanisms that ..
    Cornelia M Weyand; Fiscal Year: 2012
    ..The studies will include vaccinating RA patients with an influenza vaccine to test whether they can build sufficient T cells to be protected from infection. ..
  4. Modulation of immune senescence by androgen treatment in aged male macaques
    Henryk F Urbanski; Fiscal Year: 2013
    ..These efforts have the potential to provide a new therapeutic approach to improve immunity in the growing elderly population. ..
  5. Mucosal Immunity and Influenza Vaccines: Phenotype and Role of Activated B Cells
    HARRY BERNARD GREENBERG; Fiscal Year: 2010
    ..b>Influenza vaccines, including live attenuated influenza vaccine (LAIV) given via intranasal spay and trivalent inactivated ..
  6. Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo
    Lynda G Tussey; Fiscal Year: 2013
    ..Lastly, VaxInnate's rapid and low cost bacteria-based manufacturing can easily be transferred to endemic countries as demonstrated by a recent successful process transfer of the 2009 H1N1 pandemic vaccine. ..
  7. Predictors of Immunologic Failure in Older Adults
    David H Canaday; Fiscal Year: 2012
    ..In order to achieve this, it is necessary to have an increased understanding of the immune dysfunction in older veterans to identify what specific defects must be overcome. ..
  8. Microneedle-based immunization against pandemic influenza
    Mark R Prausnitz; Fiscal Year: 2011
    ..Aim 1 seeks to design and characterize microneedle systems to deliver influenza vaccines to skin...
  9. Effects of Maternal Influenza Immunization: A Field Trial in Guatemala'
    Saad B Omer; Fiscal Year: 2010
    ..Therefore, we propose to conduct a randomized, double-blind, controlled, vaccine trial in Guatemala to evaluate the efficacy of influenza immunization in pregnancy for protecting mothers and their infants. ..
  10. HA Surface Presented Yeast Flu Vaccine and Its Enhancement by CD154 Codisplay
    Kaiming Ye; Fiscal Year: 2012
    ..Here, a new type of potent influenza vaccines is proposed based on the PI's previous works on protein surface display...
  11. Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
    DENISE KAMINSKI; Fiscal Year: 2009
    ..S. per year. Humans can be protected by vaccination against seasonal influenza strains. However, current influenza vaccines mostly induce antibodies to the virus'external glycoproteins...
  12. Development of Cross Protective H5 Hemagglutinin Antigens
    Susan C Bock; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Because conventional influenza vaccines stimulate immune responses against parts of the virus that evolve steadily over time, it is necessary to ..
  13. Leukocyte Signaling in the Elderly and Vaccine Immunogenicity
    DAVID BRAM LEWIS; Fiscal Year: 2012
    ..These tests will help use current vaccines more effectively, and will also help in the development of a new, more potent vaccine for influenza that uses an adjuvant, a substance added to vaccines to boost the immune response. ..
  14. Influenza Immunity: Protective Mechanisms Against Pandemic Respiratory Virus
    MARK MORRIS DAVIS; Fiscal Year: 2013
    ..A second and new theme that we are pursuing is to use our analyses of responses to the two licensed influenza vaccines to establish a unique dataset and "metrics" of human immunology in which we can begin to identify biomarkers ..
  15. Surrogate endpoints for correlating protective immunity in response to influenza
    Gary Fujii; Fiscal Year: 2010
  16. T cell immunity to influenza virus in the aged nasal mucosa
    Bas Baaten; Fiscal Year: 2013
  17. Developing a Paramyxovirus-based H5N1 Vaccine
    Biao He; Fiscal Year: 2012
    ..higher concentrations of the vaccine to achieve a moderate level of efficacy compared to conventional influenza vaccines. Conventional vaccines utilizing the HA and NA of H5N1 viruses have been poorly immunogenic and have safety ..
  18. Maternal Stress, Obesity, and Influenza Virus Vaccine Immunogenicity in Pregnancy
    LISA MICHELLE CHRISTIAN; Fiscal Year: 2013
    ..This study will determine if it is justified to re-evaluate influenza vaccine recommendations for pregnant women with specific risk factors. ..
  19. Regulation of B Lymphocyte Defects in Senescent Humans
    Bonnie B Blomberg; Fiscal Year: 2013
  20. Construct novel influenza A (H1N1) virus chimeric HA genes for development of bro
    VICTOR CHESTER HUBER; Fiscal Year: 2010
    ..The long term goal of our study is to develop universal vaccines that can elicit broad immunity to prevent future pandemics. ..
  21. Function of NALT in nasal immunization to heterotypic strains of influenza
    Troy D Randall; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Cold adapted influenza vaccines (CAV) are live attenuated viruses that infect the upper respiratory tract, including the Nasal Associated Lymphoid Tissue (NALT)...
  22. Validity of Self-Reported Adult Vaccination Status
    SHARON L ROLNICK; Fiscal Year: 2010
    ..The results of this study have the potential to guide the development of future policies, resources and activities related to monitoring adult vaccination coverage in the United States. ..
  23. Effects of Tobacco Exposure on Immune Responses
    Kari C Nadeau; Fiscal Year: 2013
  24. Broadly Specific Needle-Free Vaccines against Emerging and Biothreat Viruses
    Alexander Bukreyev; Fiscal Year: 2013
  25. Integrase-defective lentiviral based influenza vaccines
    Mirella Salvatore; Fiscal Year: 2010
    ..These studies will define the utility of ID-LV as a delivery vector. If successful, this approach would represent a significant step in vaccine development given the safety feature of non-integration. ..
  26. Testing in vivo of HIV-immunopathogenic hypotheses using new kinetic techniques
    MARC KOPEL HELLERSTEIN; Fiscal Year: 2012
    ..Dandekar). In summary, the quanta! advances in measurement technology achieved in the first phase of this award now allow interesting and fundamental questions about HIV-immunopathogenesis to be addressed directly. ..
  27. Stimulation of broadly neutralizing antibodies against influenza in a pig model
    RADHEY SHYAM KAUSHIK; Fiscal Year: 2011
    ..However, such antibodies are infrequently induced either by immunization with influenza vaccines or through natural infection, suggesting that their epitope(s) are temporary and short-lived, or are ..
  28. Annual Estimates of Influenza Vaccine Effectiveness: Davidson County, TN
    Marie R Griffin; Fiscal Year: 2010
    ..we also will collect, process, store, and ship to CDC, 450 paired sera and150 paired peripheral blood mononuclear cell specimens to assess both humoral and cellular immune responses to influenza vaccines among adults aged >50 years.
  29. Contact Network Epidemiology of Influenza and Other Nosocomial Infections
    ALBERTO MARIA contact SEGRE; Fiscal Year: 2010
  30. Novel Vaccination Strategies Against Epidemic and Pandemic Influenza Viruses to I
    Murali Krishna Kaja; Fiscal Year: 2012
    ..Nearly 90% of these deaths are in elderly people. These deaths occur despite the fact that current influenza vaccines reach >65% of the adult population...
  31. Influenza vaccination using a microneedle patch
    Mark R Prausnitz; Fiscal Year: 2013
    ..The proposed Phase I clinical trial will provide the first human study of this technology. ..
  32. Vitamin D and Immunosenescence in Older Long-Term Care Residents
    Adit A Ginde; Fiscal Year: 2013
    ..Ginde become a leading investigator of interventions to improve immunosenescence and reduce the burden of infection in older adults. ..
  33. Novel Influenza A Nanovaccines for Broad Cross Protection
    Baozhong Wang; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Influenza is a worldwide public health problem. Although current influenza vaccines are effective in battling closely matched viruses, major limitations of current vaccines are the need to produce new ..
  34. Development and Maintenance of Memory CD8 T Cells
    Jianzhu Chen; Fiscal Year: 2010
    ..However, the value of current influenza vaccines is limited because they have to be reformulated every year due to waning of the elicited antibody responses ..
  35. New Vaccine against Influenza
    Mingtao Zeng; Fiscal Year: 2011
    ..This will meet the urgent need for public health. ..
  36. Vaccine strategies that target cytolic CD4 T cells to the lung.
    Deborah M Brown; Fiscal Year: 2011
    ..Therefore, it is of extreme importance to develop influenza vaccines that target T cell immunity, however, the mechanisms that direct T cell trafficking to the lung and the T ..
  37. Genome-wide genetic variation in the human immune response to influenza vaccines
    LUIS MIGUEL FRANCO; Fiscal Year: 2013 to understand how differences in human DNA may help explain why individuals respond differently to influenza vaccines. The research plan involves vaccination of healthy human volunteers against influenza and a combination of ..
  38. Immune factors in vaccine-enhanced pandemic H1N1 influenza disease
    Amy L Vincent; Fiscal Year: 2013
    ..Therefore, our long-term goal is to elucidate the pivotal factors that determine if influenza vaccines cross-protect or exacerbate disease upon infection with antigenically divergent strains...
  39. Novel nanotechnology based oral influenza vaccines
    Sang Moo Kang; Fiscal Year: 2011
    ..Our preliminary studies provide evidence that inactivated influenza vaccines can provide heterosubtypic cross protection if their immunogenicity is enhanced, and that oral vaccination ..
  40. From Innovation to Solutions: Autodialers, Use of Early Autumn Physicals and Vac
    Richard K Zimmerman; Fiscal Year: 2012
    ..These strategies will be tested in a stratified random cluster trial of primary care practices. ..
  41. NAD and CD38: modulators of inflammation and immunity
    Frances E Lund; Fiscal Year: 2010
    ..Thus, it is one of NIAID's highest priorities (NOT-AI-05-013) that we develop more effective influenza vaccines that are protective against a wide array of different viral serotypes.
  42. Antigen processing and the age-related decline in protection against influenza
    Tara Robinson; Fiscal Year: 2011
    ..The experiments we propose probe basic aspects of the immune response that may point to ways of increasing vaccine potency, a development that would be particularly beneficial to the elderly. ..
  43. Universal T cell targeted influenza vaccine
    Daniel F Hoft; Fiscal Year: 2013
    ..There is an urgent unmet need for influenza vaccines that induce greater strain cross-protective immunity...
  44. Social Networks and the Spread of Influenza and other Nosocomial Infections
    Philip M Polgreen; Fiscal Year: 2012
    ..This work will lead to more effective infection control interventions and strategies. ..
  45. Pulmonary Immunity To Pathogens In Neonates
    Troy D Randall; Fiscal Year: 2013
    ..In addition, these experiments will test the ability of recombinant influenza vaccines expressing cytokines and chemokines involved in lymphoid organ maturation to elicit robust and long-lived ..
  46. MOSAIC: Mobile Surveillance for ARI and ILI in the Community
    Melissa S Stockwell; Fiscal Year: 2013
    ..If successful this project could provide important new information to help plan ARI/ILI interventions including new vaccines, vaccination strategies, and surveillance for viral pathogens, including future outbreaks. ..
  47. Rational design of M2e-FP conserved epitope-based universal influenza A vaccines
    Lanying Du; Fiscal Year: 2012
    ..of the highly pathogenic avian influenza (HPAI) H5N1 viruses because the currently licensed seasonal influenza vaccines fail to produce cross-protection against the newly emerging influenza A viruses (IAVs)...
  48. Overcoming Immunosenescence by Nanoparticle-Mediated Activation
    Kam W Leong; Fiscal Year: 2013
    ..If proven successful, this approach could serve as a new paradigm for improving vaccines in general. ..
  49. Core_plus Option_B_C_Influenza Vaccine Effectiveness in a Wisconsin Population
    Edward Belongia; Fiscal Year: 2013
    ..abstract_text> ..
  50. New Jersey Pregnancy Risks Assessment and Monitoring System (PRAMS)- a surveillan
    INGRID MORTON; Fiscal Year: 2013
    ..Publications - Updating several NJ PRAMS data briefs are planned and will be posted on the NJ PRAMS website. Significant Project Changes - There are no significant project changes planned for 20 II. ..
  51. Rational Design of Live Attenuated Influenza A Vaccine Candidates
    Eckard Wimmer; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Despite the availability of influenza vaccines, approximately 35,000 individuals die each year in the US alone from influenza, and influenza-related complications...
  52. Burden of RSV and Influenza Virus in Children in Pakistan
    Syed Asad Ali; Fiscal Year: 2012
    ..Since influenza vaccines are currently available and RSV vaccines are in advanced development, these studies will establish baseline ..
  53. Differential Provider Interactions and Ethnic Disparities in Influenza Vaccinatio
    KATHERINE MARIE HARRIS; Fiscal Year: 2011
  54. Effect of Influenza Infection on Alveolar Macrophage Function
    Dennis W Metzger; Fiscal Year: 2012
    ..The results obtained from this study will provide a comprehensive model for understanding microbial interactions in the pulmonary tract and thus provide important insight into the development of effective therapeutics for human use. ..
  55. Development of live attenuated influenza virus vaccine
    Debi P Nayak; Fiscal Year: 2010
    ..Live attenuated vaccines can be produced in mass quantity, delivered easily and will produce broader and long lasting protective immunity against virulent influenza viruses. ..
  56. 2012 Biology of Acute Respiratory Infection Gordon Research Conference
    Alice S Prince; Fiscal Year: 2012 2007 exceeded 2 billion dollars/year in Europe alone, despite the availability of pneumococcal and influenza vaccines. The cost of RSV hospitalizations for children under 2 years of age in the US exceeds 384 million dollars ..
  57. Immunity of aged mice after lifelong repeated live or killed influenza vaccines
    DONNA MARIE MURASKO; Fiscal Year: 2012
    ..g. altered cell-mediated memory;broadly cross-reactive antibody). These studies have the potential to provide significant information regarding an important public health issue in the light of recent developments. ..
  58. Toward a Universal Influenza Virus Vaccine
    Peter Palese; Fiscal Year: 2013 the identification of broadly neutralizing antibodies and in the production of prototype broad-spectrum influenza vaccines. Our own preliminary studies, along with the combined expertise of the collaborating investigators, support ..
  59. Core_plus Option_A_C_Influenza Surveillance and Vaccine Effectiveness in a Large
    Richard K Zimmerman; Fiscal Year: 2013
    ..Using case-control methods, we propose to calculate the effectiveness of influenza vaccines against laboratory-confirmed influenza virus infections among outpatients in three age groups: 6 months-18 ..
  60. Direct and Indirect Protection by Influenza Vaccine Given to Children in India
    Wayne M Sullender; Fiscal Year: 2010
    ..The disease burden of influenza among children in India is ill defined but is likely substantial. Influenza vaccines are in routine use in children in the US, although licensed in India, they are seldom given...
  61. Center for Computational Mass-Spectrometry
    Pavel A Pevzner; Fiscal Year: 2011
    ..Educational activities in the area of computational proteomics will also be developed, including short courses, a seminar program, an annual conference, and concerted education of students and postdocs. ..
  62. In-ovo vaccination/avian influenza/bird/human
    DE CHU CHRISTOPHER TANG; Fiscal Year: 2010
    ..the poultry-to-human transmission of avian influenza by in ovo injection of adenovirus-vectored avian influenza vaccines that can be mass-produced in cultured cells and mass-administered with a mechanized injector...
  63. Rural Trial of Clinic Order Entry with Decision Support
    Matthew Samore; Fiscal Year: 2006
    ..The cost impact of the intervention will be measured to allow a comprehensive assessment of the value of this HIT. [unreadable] [unreadable]..
    Innocent Mbawuike; Fiscal Year: 2001
    ..CTL deficiency in elderly persons, then cytokine immunotherapy or formulation of cytokines with standard influenza vaccines may be designed for the development of more effective immunoprophylaxis against influenza and other ..
  65. Adjuvant-containing chimeric virus-like particles as improved influenza vaccines
    FU SHI contact QUAN; Fiscal Year: 2010
    ..Therefore, development of influenza vaccines with improved protective efficacy against influenza virus is an imperative...
  66. A Preventative Adenoviral-Based H5N1 Influenza Vaccine
    Andrea Gambotto; Fiscal Year: 2007
    ..Hence, a centralized and integrated clinical vaccine testing will be proposed. [unreadable] [unreadable] [unreadable]..
  67. Effectiveness of Hospital-Based Program for Vaccination of Birth Mothers and Hous
    Sylvia Yeh; Fiscal Year: 2009
    ..In addition, the proposal will consider the cost-benefit of a standing order related to the predicted prevention of morbidity and mortality in young infants due to pertussis and influenza. ..
  68. Microcarrier / CEF / Media SYSTEM to make Viral Vaccines
    WILLIAM HILLEGAS; Fiscal Year: 2002
    ..The research proposed has the potential to address this issue. ..
  69. Novel VLP vaccines for pandemic influenza virus
    Richard W Compans; Fiscal Year: 2010
    ..Current influenza vaccines are produced from viruses that are adapted to grow well in embryonated hens'eggs, whereas highly ..
  70. Rapid Analysis of Influenza Vaccine Effectiveness
    Edward Belongia; Fiscal Year: 2007
    ..Interim and annual estimates of VE with 95% confidence intervals will be provided to CDC, including overall VE and VE for each of the priority age groups. ..
  71. Wide Dynamic Range Hydrogen Peroxide Sensor for Sterilization Cycle Development
    WILLIAM KESSLER; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  72. Evaluating the Impact of a Large School-based Influenza Immunization Campaign
    CARLOS GRIJALVA; Fiscal Year: 2009
    ..b>Influenza vaccines have proven to be efficacious in the prevention of disease in vaccinated individuals and it has been ..
  73. Influenza Vaccine Delivery to Adolescents: two multicomponent interventions
    James Hughes; Fiscal Year: 2009
    ..Findings from this study could have important health policy implications, laying the foundation for recommendations on how best to implement a universal influenza vaccination strategy of adolescents. ..